Medicine, Hepatology Division

Fingerprint The fingerprint is based on mining the text of the scientific documents related to the associated persons. Based on that an index of weighted terms is created, which defines the key subjects of research unit

Liver Medicine & Life Sciences
Liver Transplantation Medicine & Life Sciences
Hepatocellular Carcinoma Medicine & Life Sciences
Hepacivirus Medicine & Life Sciences
Transplants Medicine & Life Sciences
Liver Diseases Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Fibrosis Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Profiles

No photo of Steven L Flamm

Steven L Flamm

Person: Academic

19942021
No photo of Daniel R Ganger

Daniel R Ganger

Person: Academic

19802021
No photo of Richard Green

Richard Green

Person: Academic

19912021

Research Output 1980 2019

A comprehensive pipeline for translational top-down proteomics from a single blood draw

Toby, T. K., Fornelli, L., Srzentić, K., DeHart, C. J., Levitsky, J., Friedewald, J. J. & Kelleher, N. L., Jan 1 2019, In : Nature Protocols. 14, 1, p. 119-152 34 p.

Research output: Contribution to journal › Article

Proteomics
Blood
Pipelines
Fractionation
Mass spectrometry
1 Citations

Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection

Flamm, S. L., Reddy, K. R., Zadeikis, N., Hassanein, T., Bacon, B. R., Maieron, A., Zeuzem, S., Bourliere, M., Calleja, J. L., Kosloski, M. P., Oberoi, R. K., Lin, C. W., Yu, Y., Lovell, S., Semizarov, D. & Mensa, F. J., Feb 1 2019, In : Clinical Gastroenterology and Hepatology. 17, 3, p. 527-535.e6

Research output: Contribution to journal › Article

Proton Pump Inhibitors
Reducing Agents
Chronic Hepatitis C
Virus Diseases
Hepacivirus
2 Citations

Epidemiology and Management of Hepatocellular Carcinoma

Kulik, L. M. & El-Serag, H. B., Jan 1 2019, In : Gastroenterology. 156, 2, p. 477-491.e1

Research output: Contribution to journal › Article

Hepatocellular Carcinoma
Epidemiology
Hepatitis C
Therapeutics
Alcoholic Fatty Liver

Grants 2002 2022

Prot# EDP 305-101: A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects with Non-alcoholic Steatohepatitis (NASH)

Rinella, M. E.

ICON Clinical Research, LLC, Enanta Pharmaceuticals, Inc.

9/11/18 → 9/12/21

Project: Research project

Prot# C928-010: An Open- Label, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Signals of DUR-928 in Patients with Alcoholic Hepatitis

Flamm, S. L.

CTI Clinical Trial and Consulting Services, DURECT Corporation

8/30/18 → 8/30/21

Project: Research project

Prot#GS-US-454-4378: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects with Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoho

Rinella, M. E.

PRA Health Sciences, Gilead Sciences, Inc.

8/23/18 → 8/23/21

Project: Research project